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Bacteria have developed several evolutionary strategies to protect
their cell membranes (CMs) from the attack of antibiotics and
antimicrobial peptides (AMPs) produced by the innate immune
system, including remodeling of phospholipid content and localiza-
tion. Multidrug-resistant Enterococcus faecalis, an opportunistic hu-
man pathogen, evolves resistance to the lipopeptide daptomycin
and AMPs by diverting the antibiotic away from critical septal tar-
gets using CM anionic phospholipid redistribution. The LiaFSR stress
response system regulates this CM remodeling via the LiaR response
regulator by a previously unknown mechanism. Here, we character-
ize a LiaR-regulated protein, LiaX, that senses daptomycin or AMPs
and triggers protective CM remodeling. LiaX is surface exposed, and
in daptomycin-resistant clinical strains, both LiaX and the N-terminal
domain alone are released into the extracellular milieu. The N-
terminal domain of LiaX binds daptomycin and AMPs (such as hu-
man LL-37) and functions as an extracellular sentinel that activates
the cell envelope stress response. The C-terminal domain of LiaX
plays a role in inhibiting the LiaFSR system, and when this domain
is absent, it leads to activation of anionic phospholipid redistribu-
tion. Strains that exhibit LiaX-mediated CM remodeling and AMP
resistance show enhanced virulence in the Caenorhabditis elegans
model, an effect that is abolished in animals lacking an innate im-
mune pathway crucial for producing AMPs. In conclusion, we report
a mechanism of antibiotic and AMP resistance that couples bacterial
stress sensing to major changes in CM architecture, ultimately also
affecting host–pathogen interactions.
antibiotic resistance | Enterococcus faecalis | daptomycin | cell membrane
adaptation | antimicrobial peptides
Antibiotic resistance has been recognized as a major globalhealth threat of the 21st century (1). Vancomycin-resistant
enterococci (VRE) are among the most challenging organisms to
treat, as some display resistance to all available antimicrobials
used in clinical practice (2). Enterococci evolved resistance under
the selective pressures of the modern health care environment due
to their genomic plasticity and ability to acquire and disseminate a
wide repertoire of antibiotic resistance determinants (3).
Daptomycin (DAP) is a frontline antibiotic against deep-
seated VRE infections (4); however, the emergence of daptomycin
resistance (DAP-R) in clinical settings emphasizes the need for
novel therapies (5). DAP is a cell membrane (CM)-acting, cationic
antibiotic that targets anionic phospholipids at the bacterial di-
vision septum (6). DAP insertion into the CM (6) leads to mis-
localization of membrane proteins involved in maintaining cell
envelope homeostasis, leading to cell death (7). Similarly, cationic
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antimicrobial peptides (AMPs) produced by the innate immune
system exert their antibacterial activity through CM disruption (8, 9).
Emergence of DAP-R in clinical and laboratory settings is
described in Enterococcus faecalis and Enterococcus faecium (5).
In E. faecalis, DAP-R is associated with changes in CM phos-
pholipid composition (10) and redistribution of anionic phos-
pholipids away from the septum, diverting DAP (11, 12). These
changes are linked to mutations in genes encoding the LiaFSR
system and enzymes involved in phospholipid metabolism (13).
LiaFSR (for lipid-II–interacting antibiotics) is a 3-component
stress response system conserved across Firmicutes that regu-
lates cell envelope integrity (14). A deletion of the gene encoding
the LiaR response regulator leads to hypersusceptibility to DAP
and AMPs (15). E. faecalis lacking LiaR is more susceptible to
killing by innate immune cells (16). Quantitative experimental
evolution has shown that pathways to DAP-R require initial
activation of the LiaFSR response followed by changes in
phospholipid enzymes (17). However, the mechanism by which
LiaR affects cell envelope integrity on exposure to antibiotics and
AMPs is unknown.
Here, we identify the genetic and biochemical basis of the
adaptive response to CM active antibiotics in E. faecalis. We
characterize LiaX, a protein of previously unknown function, as
the main mediator of the LiaR-directed CM response to DAP
and AMPs. Each domain of LiaX plays a unique function in
modulating DAP-R. The C-terminal domain of LiaX inhibits the
LiaFSR system in wild-type strains. Thus, the absence of the
C-terminal domain releases this inhibition and acts as a signal to
trigger the CM stress response. The N-terminal domain func-
tions as a sentinel that can bind DAP and AMPs in the extracellular
environment, leading to activation of the LiaFSR system and pro-
tection against antimicrobials. DAP-R strains show enhanced viru-
lence in vivo in a Caenorhabditis elegans infection model relative to
daptomycin-susceptible (DAP-S) strains due to resistance to the in-
nate immunity. Supplementing the C. elegans infection assay with the
N-terminal domain of the LiaX is sufficient to enhance the virulence
of DAP-S strains. Thus, LiaX functions as a modulator of the CM
stress response linking membrane adaptation, antibiotic resistance,
and pathogenesis.
Results
Determination of the LiaR Regulon. We hypothesized that the
biochemical mechanism of DAP-R is mediated by genes regu-
lated by the LiaFSR system. Thus, we used transcriptomics to
identify target genes in the LiaR regulon. Genes mediating DAP-R
were identified by comparing 1) a clinical strain pair of DAP-S and
DAP-R E. faecalis (S613 and R712) recovered from the blood-
stream of a patient before and after DAP therapy, respectively (13),
and 2) a DAP-R derivative of S613 that harbors the mutated alleles
from R712 [S613ΔliaF177gdpD170cls61; referred herein as TM (13)] with
its derivative that has a deletion of liaR and is hypersusceptible to
DAP (12). We identified 3 proteins encoded by the liaXYZ operon
(SI Appendix, Fig. S1) as well as genes coding for transmembrane
proteins of unknown function and proteins involved in cell envelope
stress responses, cell division, and cell wall synthesis among others
(SI Appendix, Fig. S2 and Table S3). Previous structural studies
showed that, on activation, LiaR oligomerizes, increasing its ability
to bind regulatory DNA sequences upstream of liaFSR and liaXYZ
and recruit RNA polymerase (18). Thus, we focused on liaXYZ and
used qRT-PCR to verify them as potentially important effectors of
LiaR (SI Appendix, Figs. S1 and S2 and Table S3).
The first gene of the liaXYZ cluster (liaX) encodes a 533-amino
acid (AA) protein with 2 distinct predicted domains: an
N-terminal domain composed mainly of α-helices and a
C-terminal domain formed largely of β-strands (SI Appendix, Fig.
S1). LiaX lacks predicted classical secretion signals, an LPXTG
motif, and transmembrane domains. liaY encodes a 107-AA
transmembrane protein harboring a PspC domain that is involved
in cell envelope stress adaptation in gram-negative bacteria (19).
liaZ encodes a 118-AA transmembrane protein with homology to
bacterial holins involved in the response to phage-mediated
membrane damage (20).
The C-Terminal Domain of LiaX Regulates CM Adaptation. Experi-
mental evolution of the DAP-S clinical isolate S613 identified that
mutations in liaF, liaS, or a frameshift stop codon at predicted AA
position 289 in LiaX were crucial in the initial adaptive trajectory
to DAP-R (17). Position 289 is within a protease susceptible linker
region that bridges the N- and C-terminal domains of LiaX, sug-
gesting that a C-terminal domain truncation is important for ad-
aptation to DAP. Thus, to verify the role of LiaX and the
function of the C-terminal domain, we generated a nonpolar
deletion of liaX (OG1RFΔliaX) and truncation of the C-
terminal domain (stop codon at AA 289, OG1RFliaX*289) in
a DAP-S laboratory strain of E. faecalis (OG1RF). Deletions
of liaX and the C-terminal domain-encoding region made
OG1RF resistant to DAP (8-fold increase in minimum in-
hibitory concentration [MIC]) with anionic phospholipids
redistributed away from the division septum as evidenced by
the pattern of 10-N-nonyl acridine orange staining (Fig. 1 and
SI Appendix, Fig. S3). Complementation of liaX in the mutants
reverted the resistance phenotype and reestablished septal lo-
calization of anionic phospholipids (Fig. 1 and SI Appendix,
Fig. S3). Analysis of membrane composition of major lipids in
exponential-phase cells showed an increase in phosphatidyl-
glycerol (PG) and a decrease in cardiolipin in DAP-R labora-
tory (OG1RFΔliaX, OG1RFliaX*289) and clinical (R712) strains
relative to their DAP-S counterparts, with no changes observed
in lysyl-PG (SI Appendix, Fig. S4). Complementation of liaX
(OG1RFΔliaX pAT392::liaX) fully reverted this phenotype (SI
Appendix, Fig. S4). Of note, these lipid composition changes
differ from previous studies conducted on stationary-phase
cells (10).
The deletion of liaX or its C-terminal domain led to the ac-
tivation of the LiaFSR stress response system as indicated by the
up-regulation of the liaFSR and liaXYZ gene clusters relative to
the DAP-S, OG1RF (SI Appendix, Fig. S5). Thus, the C-terminal
domain of LiaX acts as a negative regulator of the LiaFSR system,
and in the absence of this domain, constitutive activation of the
system leads to CM remodeling that modulates antibiotic resistance.
LiaX and Its N-Terminal Domain Are Released into the Extracellular
Environment in DAP-R Strains. Since LiaX has 2 distinct domains,
we hypothesized that the subcellular localization of LiaX is im-
portant for its function. Localization was probed with an enzyme-
linked immunosorbent assay (ELISA) and immunoblotting on
whole cells, cell wall or CM extracts, and concentrated super-
natants using an affinity purified antibody to the N terminus of
LiaX. All experiments were performed with pairs of DAP-R and
DAP-S clinical and laboratory strains. The 60-kDa LiaX or the N
terminus alone (∼30 kDa) was detected on the cell surface and
extracellular milieu in significantly higher amounts in all DAP-R
strains (clinical or laboratory origin) compared with the DAP-S
parental strains (Fig. 2). Notably, the N-terminal domain of LiaX
is detected along with full-length LiaX in the supernatants of the
DAP-R clinical strains (Fig. 2C).
To identify changes in LiaX localization under antibiotic ex-
posure, DAP-S and DAP-R strains were incubated with in-
creasing DAP concentrations prior to immunoblotting. LiaX was
detected in the whole-cell lysates and supernatants of DAP-S
strains in a concentration-dependent manner, while DAP-R
strains constitutively produced and released high amounts of
LiaX (SI Appendix, Fig. S6). A band corresponding to the N
terminus was also detected in strains that harbored the full-
length liaX in the lysates or supernatants, indicating that LiaX
is likely processed and that the N-terminal end is released
26926 | www.pnas.org/cgi/doi/10.1073/pnas.1916037116 Khan et al.
separately. To determine if overproduction of LiaX is sufficient
for extracellular secretion, we cloned liaX in plasmid pMSP3535
under a nisin-inducible promoter and delivered the construct to
OG1RFΔliaX. Induction with ascending concentrations of nisin
led to increased expression and eventual secretion of both full-
length and N-terminal LiaX (SI Appendix, Fig. S7). Additionally,
we sought to visualize LiaX in the extracellular milieu using
immunogold labeling and transmission electron microscopy.
More LiaX was detected in the extracellular milieu of DAP-R
compared with DAP-S strains (SI Appendix, Fig. S8). Our results
Fig. 1. LiaX regulates CM remodeling in E. faecalis. (A) Representative fluorescence microscope images of anionic phospholipids visualized in E. faecalis
strains grown to midexponential phase by staining with 10-N-nonyl acridine orange (NAO). A nonpolar deletion (OG1RFΔliaX) and a C-terminal truncation
(OG1RFliaX*289) lead to DAP-R as seen with the 8-fold increase in DAP MIC and a redistribution of anionic phospholipids away from the division septum (white
arrow). (Scale bar: 0.5 μM.) (B) Mean fluorescence intensity (relative fluorescence units [rfu]) across cell length (represented on the x axis as a fraction of the
distance from the midcell division septum) was quantified from 25 to 50 single cells for each strain, with error bars indicating the SD at each point in the cell.
Fig. 2. LiaX is highly surface exposed and released into the extracellular environment in DAP-R strains. ELISA with optical density measured at a wavelength
of 405 nm (OD405), using affinity purified antibody to the N-terminal domain of LiaX on the cell surface (A) and in TCA precipitated supernatants (B).
OG1RFΔliaX was used as a negative control. All DAP-R strains have increased detection of LiaX compared with their DAP-S counterparts. Statistics display mean
values from 3 independent experiments with 24 replicates each and error bars for SEM. ns, not significant. **P < 0.0001 (2-tailed t test). (C) Immunoblotting to
detect LiaX full length (60 kDa; upper band) or N terminus (30 kDa; lower band) in the CM, cell wall, and supernatant fractions of DAP-S and DAP-R strains. Despite
lacking identifiable transmembrane domains or LPXTG motifs, LiaX is seen in all fractions. EbpA, a cell surface pilli protein, was used as a cell wall loading control.
RNA polymerase β-subunit (RNAP β), a cytosolic protein, was used as a quality control to ensure purity of the cell wall and membrane fractions.
Khan et al. PNAS | December 26, 2019 | vol. 116 | no. 52 | 26927
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indicate that development of DAP-R involving CM remodeling
was associated with increased cell surface exposure and extra-
cellular release of LiaX and/or the N terminus of the protein.
LiaX Binds DAP and the Human Cathelicidin LL-37. To dissect the
extracellular role of LiaX, we postulated that LiaX could bind
DAP or AMPs to “shield” the cell from the antibiotic attack. The
human cathelicidin LL-37 (21) is a peptide secreted by
polymorphonuclear leukocytes to disrupt the bacterial CM and is
functionally similar to DAP. Enterococci lacking liaR are more
susceptible to killing by human neutrophils, presumably by en-
hancing the ability of LL-37 to kill the invading bacteria (16).
DAP-R has been associated with cross-resistance to AMPs, in-
cluding LL-37 (22). In agreement with those studies, all laboratory
and clinical DAP-R strains (including OG1RFΔliaX) were re-
sistant to LL-37 killing compared with their DAP-S counterparts
(SI Appendix, Fig. S9). Furthermore, reintroduction of liaX in
OG1RFΔliaX reverted the resistance phenotype. We then tested
the ability of both LiaX and the N-terminal domain to bind DAP
using fluorescence spectroscopy. The disassociation constant (Kd)
for the full LiaX protein was 30.4 ± 6.1 nM in the presence of
1 mM Ca+2, while the N-terminal domain had a modestly lower
affinity (Kd = 83.8 ± 6.6 nM) (Fig. 3A and SI Appendix, Table S4).
DAP MICs for enterococci range from ∼0.25 to over 20 μg/mL
(1.5 to 12 μM), which is more than 10 times our measured in vitro
Kd levels. Thus, LiaX binding to DAP occurs within physiologically
relevant concentrations. LL-37 binding to LiaX was measured
using microscale thermophoresis (MST) by quantifying changes in
fluorescence emitted by NT-647–labeled LiaX (Fig. 3B). The Kd
for LiaX was 8.26 ± 0.28 μM, and it was 10.6 ± 0.43 μM for the N
terminus of LiaX (SI Appendix, Table S4). There is a modest
sigmoidal character to the binding isotherms, suggesting cooper-
ativity during binding (Fig. 3B). The binding affinity of the N
terminus of LiaX to LL-37 was also verified by MST with a His
tag-specific NT-674 dye labeling LiaX, yielding a Kd similar to full-
length protein (5.268 ± 1.141 μM) (SI Appendix, Fig. S10). To
determine if the binding of the N terminus of LiaX to AMPs is
largely charge mediated, we tested an active form of dermcidin
(DCD-1L), a membrane-acting anionic AMP that is expressed in
human eccrine sweat glands. DCD-1L has broad-spectrum anti-
microbial activity, including against E. faecalis, with a mechanism
of action predicted to be distinct from that of cationic AMPs (23,
24). We confirmed that DCD-1L (50 μg/mL) was active against
OG1RF and S613 (SI Appendix, Fig. S11). However, in contrast to
LL-37, the N-terminal domain of LiaX exhibited no detectable
binding affinity to DCD-1L, even at high concentrations
(1,000 μM) (SI Appendix, Fig. S10 and Table S4). To determine if
a reduction in the cationic charge of LL-37 (+5.9) would impact
binding, we tested neutral (substituting alanine and lysine for
serine) and charge reversed (substituting some aspartate or ar-
ginine residues for lysine or glutamate, net charge −6.1) mutants
of LL-37. The binding affinity of the N-terminal domain of LiaX
to neutral LL-37 decreased by ∼10-fold, with no binding ob-
served to charge reversed LL-37 (SI Appendix, Fig. S10 and
Table S4). These findings confirm that LiaX, specifically the N-
terminal domain, binds DAP and cationic AMPs and that charge
likely plays an important role in this interaction.
Protection by LiaX against DAP Is Dependent on a Viable LiaFSR
System. Since LiaX binds DAP with high affinity, we postulated
that releasing LiaX into the environment is a bacterial strategy to
prevent DAP or AMPs from reaching the CM. Thus, we per-
formed a modified spent media assay with MIC determinations
that explored the ability of supernatants from DAP-R strains
(with excess LiaX) to protect DAP-S strains against DAP. The
DAP MIC of the DAP-S clinical isolate S613 increased when
grown in the presence of supernatants derived from DAP-R
R712 (Fig. 4A). Of note, R712 constitutively releases higher
amounts of LiaX into the medium than S613 in both the pres-
ence and absence of DAP (SI Appendix, Fig. S6). Supernatants
collected from R712 at late exponential phase yielded maximum
protection to S613 relative to those harvested from earlier growth
phases (SI Appendix, Fig. S12). This implies that higher extracellular
accumulation of LiaX by late exponential phase correlates with
increased protection. No change in the DAP MIC was observed
when OG1RF was exposed to supernatants from OG1RFΔliaX
(Fig. 4A), confirming that LiaX must be present in the environment
for protection. The DAP MIC of DAP-S OG1RF increased in the
presence of supernatants from DAP-R OG1RFliaX*289 (which se-
cretes the N-terminal domain of LiaX), indicating that the N ter-
minus is sufficient to mediate protection (Fig. 4A). We then
investigated if exogenous addition of purified LiaX or the N ter-
minus alone can protect DAP-S strains. Addition of 50 nM
N-terminal LiaX was enough to increase the DAP MIC of OG1RF
and S613 over 8-fold (Fig. 4B). Full-length LiaX was less potent,
with a 2- to 3-fold increase in the DAPMICs. Addition of a range of
1 to 100 nM N-terminal LiaX yielded a high level of protection to
OG1RF in a concentration-dependent manner, with the full-length
LiaX having a less potent effect even at 200 nM (Fig. 4C). Of note,
LiaX and its N terminus at their functional concentrations had no
impact on the growth of E. faecalis (SI Appendix, Fig. S13). Fur-
thermore, the N terminus of LiaX (and to a lesser extent, full-length
LiaX) protected OG1RF and S613 from LL-37–mediated killing (SI
Appendix, Fig. S14) in a concentration-dependent manner (SI Ap-
pendix, Fig. S14B).
To assess if the LiaX-mediated protection against DAP was
due to direct binding and titration of the antibiotic in the envi-
ronment or alternatively, through activation of an specific en-
terococcal signaling network (i.e., LiaFSR), we determined the
DAP MIC of DAP-S Staphylococcus aureus ATCC29213 (DAP
MIC of 0.5 μg/mL) in the presence of supernatants from
OG1RFliaX*289 (Fig. 4A) and with the addition of exogenous
LiaX or the N terminus of LiaX (Fig. 4B). The DAPMIC did not
change under any condition, suggesting that the LiaX-mediated
effect is specific to E. faecalis and that LiaX does not merely se-
quester DAP to prevent it from binding to the CM. Furthermore,
we examined whether the LiaX-protective effect relied on an ac-
tive LiaFSR system by testing changes on DAP MICs of OG1RF
lacking liaR using supernatants from OG1RFliaX*289 and after
addition of exogenous LiaX or N-terminal LiaX. The super-
natant of OG1RFliaX*289 (Fig. 4A) or the addition of LiaX or
N-terminal LiaX (Fig. 4B) did not protect OG1RFΔliaR
against DAP. Moreover, LiaX and the N terminus of LiaX did
not protect OG1RFΔliaR from LL-37–mediated killing (SI
Appendix, Fig. S14A). Thus, we conclude that the mechanism of
Fig. 3. LiaX and the N terminus of LiaX can bind antimicrobial molecules
with high affinity. (A) Fluorescence spectroscopy measuring full-length LiaX
(FL-LiaX) or N-terminal domain of LiaX (NTD) and DAP binding affinity using
the intrinsic fluorescence of DAP (at 465 nm) and increasing concentrations
of LiaX or the N terminus of LiaX in the presence of 1 mM Ca2+. (B) MST
measuring LiaX or the N terminus of LiaX and LL-37 binding affinity in the
presence of increasing concentrations of fluorescein-labeled LiaX. Statistics
were performed on data from 3 independent experiments.
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LiaX-mediated protection against antimicrobials requires an
intact LiaFSR system.
LiaX-Mediated Activation of LiaFSR Requires the Presence of DAP. To
determine if the basis of the mechanism of extracellular pro-
tection mediated by LiaX or the N terminus of LiaX was a
specific response dependent on the presence of cell envelope
stress or a stochastic phenomenon due to production of high
levels of LiaX in the cellular environment, we assessed the
transcriptional activation of liaFSR and liaXYZ in the presence
of LiaX or its N-terminal domain by qRT-PCR. Fig. 4D shows
that adding 50 nM purified LiaX or the N terminus of LiaX in
the media of DAP-S OG1RF had no effect on the levels of
transcription of the gene clusters relative to untreated controls.
However, when DAP (at subinhibitory concentrations) and pu-
rified N terminus of LiaX were added, the liaFSR and liaXYZ
operons were highly up-regulated, correlating with maximal ac-
tivation of the LiaFSR stress response. This is consistent with our
in vitro binding studies (Fig. 3A and SI Appendix, Fig. S10 and
Table S4) that suggest that the majority of LiaX would be bound
to DAP under these conditions. Most notably, LiaFSR activation
with addition of the N terminus of LiaX plus DAP was signifi-
cantly higher and more pronounced than that of treatment with
DAP alone or DAP with full-length LiaX (Fig. 4D).
LiaX Mediates Enhanced Virulence In Vivo Due to Resistance to Host
Innate Immunity. Inactivation of the LiaFSR system increases the
ability of human innate immune cells to clear both E. faecalis and E.
faecium (16). Our binding studies showed that LiaX binds LL-37
with high affinity (Fig. 4B and SI Appendix, Fig. S10), which led us
to postulate that LiaX may play a role in E. faecalis pathogenesis
and mediate resistance to other host-derived AMPs. We tested this
hypothesis by using the C. elegans infection model (25). Both
clinical- (Fig. 5A) and laboratory-derived (Fig. 5B) DAP-R strains
displayed increased virulence as measured by nematode killing
compared with their DAP-S parental strains. To determine if the
enhanced virulence was mediated by increased resistance to AMPs
produced by the innate immune system, we tested the ability of E.
faecalis to infect nematodes lacking the p38 MAP kinase pathway
(Δpmk-1), a key immune pathway that regulates important im-
mune effectors, including CM disrupting AMPs (26). Consistent
with our hypothesis, DAP-R strains had no virulence advantage
over their DAP-S counterparts when infecting the Δpmk-1 worms
(Fig. 5 C and D).
Since the N terminus of LiaX serves as a potent signaling
molecule that can interact with AMPs, we hypothesized that
supplementing the N terminus of LiaX into the media would
modulate virulence of E. faecalis in the C. elegans model. Indeed,
OG1RF and S613 were more virulent on addition of the N ter-
minus of LiaX (Fig. 6) in a dose-dependent manner (SI Appendix,
Fig. S15A). Addition of exogenous N terminus of LiaX did not,
however, alter the virulence of OG1RF ΔliaR and TM ΔliaR (Fig.
6 and SI Appendix, Fig. S15B). Of note, addition of the N terminus
alone was not toxic to the worms (SI Appendix, Fig. S15C). These
results suggest that the N terminus of LiaX contributes to in-
creased virulence in vivo by mediating E. faecalis protection
against AMPs produced by the innate immune system.
Discussion
We have previously shown that the LiaFSR system regulates DAP
and AMP resistance in enterococci (12, 15) by causing major
changes in the cell envelope, including alterations of CM phos-
pholipid content and architecture (11, 27). Here, we characterize a
protein LiaX, a previously unknown mediator of the CM adaptive
Fig. 4. Extracellular LiaX protects DAP-S strains from DAP attack by activating the LiaFSR stress response. (A) Spent medium assay, with DAP MIC for DAP-S
strains (first listed strain) determined in the presence of medium from exponential growth of DAP-R strains (denoted M). Spent media from DAP-R strains
protect DAP-S E. faecalis strains from DAP attack in an LiaR-dependent manner. MIC was measured for each condition in 3 independent experiments with 3
replicates each, and statistics were calculated by 1-way ANOVA. **P < 0.001. (B) DAP MIC determination for DAP-S strains by broth microdilution grown with
exogenous LiaX or N-terminal LiaX at 50 nM supplemented in the media. Data are an average of 3 experiments with statistics calculated by a 1-way ANOVA.
*P < 0.01, **P < 0.001. (C) DAP MIC determination of OG1RF by broth microdilution in the presence of increasing concentrations of LiaX or the N terminus of
LiaX. Data are an average of 3 experiments with statistics calculated by a 1-way ANOVA. *P < 0.01, **P < 0.001. (D) Quantitative real-time PCR for liaFSR and
liaXYZ expression. Statistics compare expression levels with untreated OG1RF and compare DAP plus LiaX or the N terminus of LiaX conditions with DAP
alone calculated by 1-way ANOVA. Addition of LiaX and the N terminus of LiaX in the presence of DAP leads to maximal activation of the LiaFSR cell
envelope stress response in OG1RF. Data are shown from 3 experiments with 3 biological replicates each. ns, not significant; WT, wild type. **P < 0.001.
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response to antibiotics and AMPs, as a main modulator of the
LiaFSR system. Each domain of LiaX serves a different function.
In a DAP-S strain, LiaX is surface exposed, and the C-terminal
domain inhibits the LiaFSR system, potentially through the
membrane-embedded regulators, LiaF and LiaS (Fig. 7A). Thus,
DAP-R can evolve via 2 pathways. A C-terminal domain trunca-
tion of liaX (17) releases the inhibition that this domain has on
LiaFSR, leading to CM remodeling and DAP-R. Additionally,
mutations in liaFSR that occur in clinical settings (11, 13) can
activate the system and lead to overexpression and extracellular
release of LiaX. When LiaX is overexpressed, both the full-length
and N-terminal domains are detected in the extracellular envi-
ronment. We hypothesize that these 2 forms of LiaX play distinct
roles, where the N terminus of LiaX specifically serves as a sen-
tinel to sense and bind antimicrobials to activate the envelope
stress response, potentially signaling through other transmembrane
components of the LiaFSR system (Fig. 7B). In the absence of
environmental stressors, the full-length LiaX is able to again bind
the membrane-associated regulators, down-regulating gene expres-
sion. This would turn “OFF” the stress response in the absence of
antimicrobials, allowing anionic phospholipids to localize to the
division septum. Both pathways (namely, a C-terminal truncation or
secretion of LiaX) lead to CM remodeling, with anionic phospho-
lipids diverted from the septum causing DAP to bind away from its
septal targets (11). Each of these strategies converges in clinical
resistance, with elimination of the bactericidal activity of DAP and
AMPs and also, resulting in increased virulence in vivo. In-
terestingly, despite lacking transmembrane domains, LPXTG mo-
tifs, or a classical secretion signal, LiaX is surface exposed and
detected in CM fractions. We thus speculate that the other genes in
the operon (liaYZ) that encode transmembrane proteins are likely
to contribute to the signaling cascade and function as interacting
partners of LiaX. Further study is needed to elucidate how LiaX is
transferred to the extracellular environment.
CM remodeling can have important consequences on en-
terococcal virulence in vivo (12). We have previously shown that
DAP-R enterococci have an increased ability to survive inside
human phagocytes (16). Here, we show that LiaX and specifi-
cally, the N-terminal domain bind LL-37 with high affinity. LiaX
mediates increased virulence in C. elegans, and DAP-R strains
have no virulence advantage over DAP-S strains when the innate
immune system, responsible for the production of AMPs, is not
functional. The N terminus of LiaX alone is able to increase the
virulence of E. faecalis (laboratory and clinical isolates) in C.
elegans. Thus, when mutations in liaFSR lead to the extracellular
release of the N-terminal domain, AMPs produced by the innate
immune system are sensed by LiaX, triggering the CM adaptive
response (Fig. 7B) and enhancing virulence. Furthermore,
LiaFSR mediates bacterial resistance to environmental stressors
in natural niches (28). Mutations in liaR were shown to enhance
VRE gastrointestinal (GI) tract colonization in a mouse model
by promoting resistance to lithocholic acid, a bile acid found
exclusively in the GI tract (29). Thus, in clinical settings, changes
in LiaX could favor enterococcal colonization, resistance against
metabolic stressors, and the host innate immunity. Such an
adaptive response could also serve as a major selective pres-
sure for developing resistance to DAP during the colonization/
Fig. 5. DAP-R leads to increased virulence in vivo due to innate immune resistance. Lethality of clinical (A) or laboratory isolates (B) in a wild-type (WT) C.
elegans infection assay. DAP-R phenotype for each strain is indicated in parentheses. Resistant isolates are more virulent than their DAP-S counterparts. These
differences in virulence are abolished when using C. elegans harboring a pmk-1 deletion lacking the primary p38 MAP kinase innate immune pathway (C andD).
The figure represents results from 3 independent experiments with 60 to 90 worms. NS, not significant. **P < 0.05.
Fig. 6. Addition of N terminus of LiaX leads to increased virulence of DAP-S
laboratory (OG1RF) and clinical (S613) strains in C. elegans. C. elegans in-
fection assay performed with laboratory strain OG1RF or clinical strain S613
and their liaR deletion derivatives (OG1RFΔliaR and TMΔliaR, respectively)
in the presence or absence of 100 nM purified N-terminal LiaX. Data are
represented as average from 3 independent experiments with 60 to 90
nematodes, and significance was calculated with a 1-way ANOVA. ns, not
significant. **P < 0.001.
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infection process, jeopardizing the therapeutic efficacy of this
antibiotic (30). Moreover, our findings on LiaX mediating re-
sistance to the innate immunity could also explain the fact that
some clinical enterococcal strains exhibit resistance to DAP,
even in the absence of actual exposure to the antibiotic (5).
In summary, our results highlight the major role of a single
protein in orchestrating the cell envelope stress response to antibi-
otics, influencing membrane adaptation and virulence. This critical
function suggests that LiaX could be a potential target for de-
veloping antiadaptation molecules that could potentially restore the
effectiveness of widely used antimicrobials and enhance innate im-
munity mechanisms to clear multidrug-resistant infecting bacteria.
Materials and Methods
Microbiology and Molecular Biology Methods. Strains and primers used in this
study are listed in SI Appendix, Table S1 and S2, respectively. Standard cul-
ture media were used for routine strain and plasmid propagation as de-
scribed in SI Appendix, SI Materials and Methods. The liaX mutants (full
deletion, C-terminal truncation) were constructed as described to create an
in-frame, nonpolar deletion using the PheS* counterselection system (31, 32)
and complemented with pAT392 (33). Recombinant LiaX and the N-terminal
domain with a His tag and SUMO tag approach were expressed in pET-Duet
vector in Escherichia coli BL-21 and purified using a nickel column
method (18). For immunoblotting, cell wall extracts were prepared
from midexponential-phase cultures using the lysozyme treatment method
(34) with membranes isolated by ultracentrifugation at 100,000 × g for 1 h,
and supernatants were isolated from the same cultures by 10% trichloro-
acetic acid (TCA) precipitation. A spent medium assay was used to determine
MICs on DAP-S strains in the presence of their own or DAP-R strains spent
medium collected at early, mid, and late exponential phases following
clinical and laboratory standards institute guidelines. Broth microdilution
was performed to determine MICs in the presence of purified LiaX. MICs
were read 24 h postinoculation. AMP killing assays were performed in RPMI
1640 media + 5% Luria–Bertani broth for 2 h with a 103 inocula or 10 mM
sodium phosphate buffer + 100 mM NaCl for 4 h with a 106 inocula for 50
μg/mL LL-37 or dermcidin (DCD-1L), respectively (12, 23). Colony-forming
unit counts compared survival with the peptide relative to the untreated
control. Statistics were calculated between 3 independent experiments with
3 biological replicates with 1-way ANOVA (P < 0.01).
Transcriptional Profiling and Quantitative Real-Time PCR. Transcriptome
shotgun sequencing comparing DAP-R and DAP-S strains was performed on
midexponential-phase cultures in 3 biological replicates with standard RNA
extraction. RNA was quality controlled by bioanalyzer and Nanodrop prior to
subjecting to RNA sequencing analysis. DNA Illumina libraries were then
sequenced on the HiSeq2000. Complete genome of R712 was sequenced for
reference with PacBio. Reads per kilobase million values, read mapping, and
alignment (35) for differential expression analysis (36) were performed using
a negative binomial fitted model with a Fischer’s exact test. qRT-PCR analysis
conducted in 3 experiments and 3 biological replicates was performed on
exponential-phase cultures grown in the presence or absence of DAP in
some instances, as indicated, followed by standard RNA extraction and
subsequently, by complementary DNA (cDNA) synthesis and evaluation of
gene expression with 5 ng cDNA using SYBR Green. The gyrB and gdhA
housekeeping genes were used for normalization. Differential gene ex-
pression was analyzed with 1-way ANOVA (P < 0.01).
Lipid Extraction and 2-Dimensional Thin-Layer Chromatography (TLC). Strains
were grown to midexponential phase in tryptic soy broth, extracted using a
modified Bligh and Dyer method prior to spotting on HPTLC Silica Gel 60
Plates (Millipore), and separated by 2-dimensional TLC (37, 38). Spots de-
veloped in CuSO4 + 8% phosphoric acid heated at 180 °C were identified
based on previous studies and lipid standards (Avanti Polar Lipids). Relative
quantification was performed through ImageJ, with results displayed as an
average of 4 biological replicates and statistics calculated by a 1-way ANOVA
(P < 0.05).
Protein Localization Analysis. Affinity-purified polyclonal anti-rat antibodies
raised in house were used for all protein detection assays. Surface exposure
and extracellular LiaX were analyzed with an ELISA (39) using an antibody to
the N terminus of LiaX performed on exponentially growing whole cells or
filter-sterilized and TCA-precipitated supernatants, respectively. Data were
compiled from 3 independent experiments with 24 technical replicates for
each strain. Two-tailed unpaired t test was used for statistics comparing
DAP-R and DAP-S pairs in addition to all strains relative to OG1RFΔliaX as
negative control. Cell wall extracts and supernatants were normalized using
the bicinchoninic assay prior to immunoblotting with the Thermo Fischer
iBlot2 and iBind Flex systems. Antibodies to RNA polymerase β-subunit and
EbpA, a pilin subunit embedded in the enterococcal cell wall, were used as a
cell wall extract quality control.
Microscopy Methods. Anionic phospholipids were visualized by staining with
10-N-nonyl acridine orange and fluorescence microscopy as described before
(11) with Olympus 1 × 71 or Keyence BX-700 using a cumulative of 3 ex-
periments with 3 biological replicates. Fluorescence intensity was quantified
by averaging the relative fluorescence units across cell length for 25 to 50
cells per strain on ImageJ. Immunogold labeling and transmission electron
microscopy were performed, as described previously (40), with antibody to
Fig. 7. Mechanistic model of LiaX-mediated DAP-R and antimicrobial peptide resistance. (A) The LiaFSR stress response system is in the OFF state in a DAP-S
strain under unstressed conditions. LiaX, expressed at basal levels, localizes on the cell surface. The C- and N-terminal domains of LiaX have unique functions.
The C-terminal domain likely inhibits the LiaFSR system, while the N-terminal domain faces the extracellular milieu (ECM). The regulators, LiaF and LiaS
(histidine kinase sensor), are embedded in the CM. (B) A strain becomes DAP resistant through activation of the LiaFSR system due to mutations in liaFSR and/
or via a C-terminal truncation of LiaX. LiaX and the N terminus of LiaX are both released into the ECM. In the presence of antimicrobials, like DAP or LL-37,
LiaX, in particular the N-terminal domain, serves as a sentinel to bind, activate, and maintain the LiaFSR response. The signaling cascade leads to
phosphorylation-dependent oligomerization of the LiaR response regulator, which up-regulates liaFSR and liaXYZ expression. Both pathways lead to CM
remodeling with changes in the architecture of anionic phospholipid microdomains and diversion of DAP away from the division septum.
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the N terminus of LiaX with anti-rat Immunoglobulin G antibody conjugated
to 18-nm gold nanoparticles. Samples with 3 biological replicates were im-
aged using a JEOL JEM 1400 120-kV microscope.
LiaX and Antimicrobial Molecule Binding Assays. Determination of LiaX
binding affinity to DAP, LL-37 variants, and dermcidin was performed with
fluorescence spectroscopy or MST (41). For DAP, the excitation was at 365 nm
with emission at 465 nm to observe Kyn-13–emitted fluorescence in the
presence of increasing LiaX concentrations. MST experiments were per-
formed on Monolith NT.115 using 25% light-emitting diode with LiaX NT-
647 labeled (in 0.1 M phosphate buffer, pH 7.4, 0.0027 M potassium chloride,
0.137 M NaCl, and 1 mM Tris [2-carboxyethyl] Phosphine with or without 5%
dimethyl sulfoxide) and tested in the presence of increasing LL-37 variant or
dermcidin concentrations. Data analysis was performed with Nanotemper
software v1.5.41.
C. elegans Infection Model. In order to assess virulence of DAP-R strains rel-
ative to their susceptible counterparts, we used a C. elegans infection model
as previously described (25). Briefly, 60 to 90 synchronized young adult
nematodes [wild type or pmk-1(km25)] (26) were infected with E. faecalis
strains on brain heart infusion (BHI) agar containing gentamicin (10 μg/mL).
For assays with exogenous LiaX, a modified liquid killing assay was per-
formed (42) by transferring worms to 20% BHI broth, 80% M9W buffer, and
the N terminus of LiaX (0.1 to 500 nM). The plates were incubated at 25 °C,
and worm death was scored daily. Kaplan–Meier log rank analysis was used
to compare survival curves pairwise (P < 0.05) calculated from 3 independent
experiments.
Data Availability Statement. All datasets, including genome sequences for
S613 and R712, have beenmade publicly available. Genomes are deposited to
the National Center for Biotechnology Information database, https://
www.ncbi.nlm.nih.gov/genome, under accession numbers CP036247–
CP036249. SI Appendix includes detailed experimental protocols and refer-
ences for the original protocols that were modified or adapted. All unique
materials (e.g., genetically altered bacterial strains, plasmids, antibodies) will
be made available from the corresponding author on request.
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